Quantinno Capital Management LP Takes $431,000 Position in Kestra Medical Technologies, Ltd. $KMTS

Quantinno Capital Management LP acquired a new stake in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 21,633 shares of the company’s stock, valued at approximately $431,000.

Several other hedge funds have also recently bought and sold shares of KMTS. Millennium Management LLC bought a new position in Kestra Medical Technologies during the first quarter valued at about $11,036,000. Woodline Partners LP bought a new stake in shares of Kestra Medical Technologies during the 1st quarter worth about $2,510,000. Jane Street Group LLC acquired a new position in shares of Kestra Medical Technologies during the 1st quarter valued at about $756,000. Geode Capital Management LLC raised its stake in shares of Kestra Medical Technologies by 718.5% in the 2nd quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock valued at $5,395,000 after acquiring an additional 285,579 shares in the last quarter. Finally, JPMorgan Chase & Co. bought a new position in shares of Kestra Medical Technologies in the 2nd quarter valued at approximately $256,000.

Kestra Medical Technologies Trading Down 1.0%

Kestra Medical Technologies stock opened at $26.99 on Friday. Kestra Medical Technologies, Ltd. has a 52 week low of $15.42 and a 52 week high of $30.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. The firm has a market capitalization of $1.58 billion, a PE ratio of -11.15 and a beta of 0.58. The business’s 50-day simple moving average is $24.57 and its 200-day simple moving average is $22.80.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The business had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. Equities research analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on KMTS shares. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. Weiss Ratings raised shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. BTIG Research upped their price objective on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, JPMorgan Chase & Co. started coverage on shares of Kestra Medical Technologies in a report on Monday, August 10th. They set an “overweight” rating and a $30.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $28.14.

Insider Activity at Kestra Medical Technologies

In other news, insider Brian Daniel Webster sold 51,900 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $24.52, for a total value of $1,272,588.00. Following the sale, the insider owned 475,215 shares in the company, valued at approximately $11,652,271.80. This trade represents a 9.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Timothy P. Moran sold 8,759 shares of the business’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $22.61, for a total transaction of $198,040.99. Following the transaction, the insider directly owned 68,725 shares in the company, valued at $1,553,872.25. This trade represents a 11.30% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 238,164 shares of company stock valued at $5,700,952. 5.30% of the stock is owned by corporate insiders.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.